prenetics im8xgcxvf.htm

Prenetics Global Limited has announced a $1 billion Customer Value Fund (CVF) arrangement with General Catalyst (GC), described by the company as non-dilutive growth financing to accelerate the growth of its IM8 premium supplement brand. Under the structure, GC provides up to 70% of the marketing spend that IM8 elects to fund each month, with each month's new customers forming a cohort that is tracked separately. Repayment is self-liquidating, drawn from the revenue those cohorts generate, and GC's exposure is limited to each cohort's performance with no recourse against the parent balance sheet and no cross-collateralization between cohorts, according to the company's presentation.

The company's financial figures, which are unaudited except FY2025, show IM8 FY2025 revenue of $60M based on audited statements. Prenetics raised its IM8 FY2026 revenue guidance to $210M-$220M from $190M-$210M and projected FY2027 revenue of $400M or more, with year-end 2026 annualized run-rate revenue (ARR) of approximately $300M. The company reported cash and liquid investments of roughly $139.7M as of May 31, 2026, and no debt. Monthly revenue rose from $0.4M at launch in December 2024 to a preliminary $17M in June 2026, which the company says is unaudited.

Payback economics are presented as a blended GC premium of 4.7% to 7.6% depending on payback speed, with a hard cap of 1.17x on the return multiple. The company states that mature cohorts (2024, 2025 and Q1 2026) pay back in approximately three to six months. Across 248,536 customers acquired from Q4 2024 through Q1 2026, the company reports $46.2M in sales and marketing spend and $66.7M in cumulative gross profit at a 58% contractual gross margin, or 1.44x blended GP/CAC. Management notes that Q1 2026 gross margin was 64% on an unaudited basis, and that customer acquisition cost rose to $305 in Q1 2026 from $104 in Q1 2025 while first-order subscriber AOV rose to $266.

The company describes the facility as illustrative rather than guidance and says the arrangement is intended to fund customer acquisition at roughly $60M per month from 2028 onward. Investors should note that the cohort payback data is company-reported, that several cohorts remain immature, and that the blended premium and gross margin assumptions are management estimates.